. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: J Thromb Haemost. 2021 Apr 12;19(7):1709–1717. doi: 10.1111/jth.15282

Table 1.

Demographics of the Patients^*.

Characteristic	Simvastatin (N= 114)	Placebo (N=113)
Age yr	62.8±8.8	62.0±8.2
Sex - n (%) Female	47 (41.2%)	54 (47.8%)
Black - n (%)	24 (21.1%)	21 (18.6%)
FEV1 - % of predicted value	44.4±17.0	42.3±18.0
Smoking history - pack year	47.0±23.6	51.4±28.1
Current Smoking Status - n (%)	38 (33.3%)	40 (35.4%)
Body Mass Index, BMI- (kg/m²)	26.8±5.8	27.7±8.1
High Blood Pressure - n (%)	48 (42.1%)	40 (35.4%)
History of Clots - n (%)	4 (3.5%)	2 (1.8%)
Cirrhosis - n (%)	2 (1.8%)	1.0 (0.9%)
Cancer - n (%)	8 (7.0%)	15 (13.3%)

Shown are means ± SD. There were no significant differences between the simvastatin and the placebo groups. FEV1 denotes forced expiratory volume in 1 second.